

Neola Medical's CEO shares recent company highlights in winter 2025 investor letter

As 2025 draws to a close, Neola Medical reflects on a year shaped by meaningful clinical progress and continued organizational strengthening. During the winter, the company further reinforced its technological and intellectual property foundation, supporting long-term development. Preparations for clinical progression also continued through site visits at leading neonatal intensive care units in the U.S.

"2025 has been a year of important clinical and organizational progress for Neola Medical. With a solid technological and intellectual property foundation, we continue to move forward in both our clinical development and organizational growth," says CEO Hanna Sjöström.

Read more in the investor letter winter 2025, attached to this press release and available on the company's website www.neolamedical.com

For further information, contact:

Hanna Sjöström, CEO

e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical

Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung complications in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on a spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola Medical builds on Sweden's longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company's Certified Adviser is FNCA Sweden AB.

Attachments

Neola Medical's CEO shares recent company highlights in winter 2025 investor letter Neola Medical Investor Letter Winter 2025